TTIPF (Thiogenesis Therapeutics) OCF Yield %: -20.36 (As of Jun. 24, 2026)


TTIPF Thiogenesis Therapeutics Corp TTIPF
12 GF Score
Price $0.42
! 1 Warning Sign
View Full Analysis

What is Thiogenesis Therapeutics OCF Yield %?

Thiogenesis Therapeutics TTIPF -6.67% 12 OCF Yield % is -20.36 as of Jun. 24, 2026. GuruFocus rates TTIPF with a GF Score™ of 12/100. The stock has 1 warning sign investors should review. Among 1,418 Biotechnology companies, Thiogenesis Therapeutics ranks worse than 68.34% on this metric.

OCF Yield % is calculated as Cash Flow from Operations divided by Market Capitalization. It is a financial solvency ratio that compares the operating cash flow a company is expected to earn against its market value.

As of today, Thiogenesis Therapeutics's Trailing 12-Month Cash Flow from Operations is $-4.29 Mil, and Market Cap is $20.50 Mil. Therefore, Thiogenesis Therapeutics's OCF Yield % for today is -20.36%.

The historical rank and industry rank for Thiogenesis Therapeutics's OCF Yield % or its related term are showing as below:

TTIPF' s OCF Yield % Range Over the Past 10 Years
Min: -20.36   Med: 0   Max: -20.36
Current: -20.36

During the past 7 years, the highest OCF Yield % of Thiogenesis Therapeutics was -20.36%. The lowest was -20.36%. And the median was %.

TTIPF's OCF Yield % is ranked worse than
68.34% of 1418 companies
in the Biotechnology industry
Industry Median: -8.55 vs TTIPF: -20.36

Thiogenesis Therapeutics's OCF Margin % for the quarter that ended in Mar. 2026 was %.

Thiogenesis Therapeutics OCF Yield % Explanation

Similar to Earnings Yield %, OCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high operating cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.

Thiogenesis Therapeutics OCF Yield % Related Terms

Thiogenesis Therapeutics OCF Yield % Historical Data

* Premium members only.

The historical data trend for Thiogenesis Therapeutics's OCF Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Thiogenesis Therapeutics OCF Yield % Chart

Thiogenesis Therapeutics Annual Data
Trend Dec19 Dec20 Feb21 Feb22 Dec23 Dec24 Dec25
OCF Yield %
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 -14.46

Thiogenesis Therapeutics Quarterly Data
Dec20 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
OCF Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -11.35 -4,626.73 -20.30 -18.28 -10.38

TTIPF vs VRTX, REGN, ALNY: OCF Yield % Comparison

For the Biotechnology subindustry, Thiogenesis Therapeutics's OCF Yield %, along with its competitors' market caps and OCF Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Thiogenesis Therapeutics OCF Yield % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Thiogenesis Therapeutics's OCF Yield % distribution charts can be found below:

* The bar in red indicates where Thiogenesis Therapeutics's OCF Yield % falls into.


TTIPF
12GF Score
Thiogenesis Therapeutics Corp TTIPF
OCF Yield % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Thiogenesis Therapeutics OCF Yield % Calculation

OCF Yield % is a financial solvency ratio that compares the operating cash flow a company is expected to earn against its market value.

Thiogenesis Therapeutics's OCF Yield % for the fiscal year that ended in Dec. 2025 is calculated as

OCF Yield %=Cash Flow from Operations / Market Cap
=-4.373 / 30.2411224
=-14.46%

Thiogenesis Therapeutics's annualized OCF Yield % for the quarter that ended in Mar. 2026 is calculated as

OCF Yield %=Cash Flow from Operations * Annualized Factor / Market Cap
=-0.515 * 4 / 19.85474308
=-10.38%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about OCF Yield % →
What does a OCF Yield % of -20.36 mean?
Thiogenesis Therapeutics (TTIPF) has a OCF Yield % of -20.36 as of Jun. 24, 2026. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on Thiogenesis Therapeutics and its competitors. According to the industry distribution chart, Thiogenesis Therapeutics ranks #969 out of 1418 companies in the Biotechnology industry, placing it in the top 68.3%.
Is Thiogenesis Therapeutics' OCF Yield % too high?
Thiogenesis Therapeutics' current OCF Yield % is -20.36. Based on the distribution chart, Thiogenesis Therapeutics ranks #969 out of 1418 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Thiogenesis Therapeutics has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Thiogenesis Therapeutics' OCF Yield % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Thiogenesis Therapeutics ranks #969 out of 1418 companies for OCF Yield %. This places Thiogenesis Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Yield % for a Biotechnology company?
A good OCF Yield % depends on the Biotechnology industry context. However, OCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Yield % mean?
A high OCF Yield % can signal that a stock is expensive relative to its fundamentals. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on Thiogenesis Therapeutics and its competitors. Thiogenesis Therapeutics's current OCF Yield % is -20.36. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Thiogenesis Therapeutics stock overvalued right now?
Thiogenesis Therapeutics (TTIPF) has a current OCF Yield % of -20.36. The current OCF Yield % is -20.36. Thiogenesis Therapeutics' overall GF Score™ is 12/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Yield % calculated?
OCF Yield % is calculated from a company's financial statements. For Thiogenesis Therapeutics (TTIPF), the current OCF Yield % is -20.36 as of Jun. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Thiogenesis Therapeutics Business Description

Other Exchanges Q8M:GermanyTTI:Canada
Address 4 King Street West, Suite 401, Toronto, ON, CAN, M5H 1B6
Thiogenesis Therapeutics Corp is a clinical-stage biotechnology company developing TTI-0102, a novel controlled-release cysteamine prodrug designed to improve tolerability and dosing relative to existing therapies. The Company is focused on TTI-0102 in nephropathic cystinosis, where it is in late-stage development, and is also conducting research and clinical development activities for primary mitochondrial diseases, including Leigh syndrome spectrum disorders.
12GF Score

Get the complete analysis for TTIPF

OCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.42
Price